XML 74 R11.htm IDEA: XBRL DOCUMENT
v3.25.3

Earnings Per Share | 9 Months Ended
--- | ---
Sep. 30, 2025
Earnings Per Share [Abstract] |
Earnings Per Share | Earnings Per ShareAbbVie grants certain restricted stock units (RSUs) that are considered to be participating securities. Due to the presence of participating securities, AbbVie calculates earnings per share (EPS) using the more dilutive of the treasury stock or the two-class method. For all periods presented, the two-class method was more dilutive. The following table summarizes the impact of the two-class method:
|  | Three months ended September 30, |  | Nine months ended September 30,
(in millions, except per share data) |  | 2025 |  | 2024 |  | 2025 |  | 2024
Basic EPS |  |  |  |  |  |  |  |
Net earnings attributable to AbbVie Inc. |  | $ | 186 |  |  | $ | 1,561 |  |  | $ | 2,410 |  |  | $ | 4,300 |
Earnings allocated to participating securities |  | 10 |  |  | 10 |  |  | 30 |  |  | 30 |
Earnings available to common shareholders |  | $ | 176 |  |  | $ | 1,551 |  |  | $ | 2,380 |  |  | $ | 4,270 |
Weighted-average basic shares outstanding |  | 1,769 |  |  | 1,769 |  |  | 1,769 |  |  | 1,769 |
Basic earnings per share attributable to AbbVie Inc. |  | $ | 0.10 |  |  | $ | 0.88 |  |  | $ | 1.35 |  |  | $ | 2.41 |
Diluted EPS |  |  |  |  |  |  |  |
Net earnings attributable to AbbVie Inc. |  | $ | 186 |  |  | $ | 1,561 |  |  | $ | 2,410 |  |  | $ | 4,300 |
Earnings allocated to participating securities |  | 10 |  |  | 10 |  |  | 30 |  |  | 30 |
Earnings available to common shareholders |  | $ | 176 |  |  | $ | 1,551 |  |  | $ | 2,380 |  |  | $ | 4,270 |
Weighted-average shares of common stock outstanding |  | 1,769 |  |  | 1,769 |  |  | 1,769 |  |  | 1,769 |
Effect of dilutive securities |  | 3 |  |  | 3 |  |  | 3 |  |  | 3 |
Weighted-average diluted shares outstanding |  | 1,772 |  |  | 1,772 |  |  | 1,772 |  |  | 1,772 |
Diluted earnings per share attributable to AbbVie Inc. |  | $ | 0.10 |  |  | $ | 0.88 |  |  | $ | 1.34 |  |  | $ | 2.41 |
Certain shares issuable under stock-based compensation plans were excluded from the computation of EPS because the effect would have been antidilutive. The number of common shares excluded was insignificant for all periods presented.

X
- References No definition available. + Details
Name: | us-gaap_EarningsPerShareAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for earnings per share. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/260/tableOfContent Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3 + Details
Name: | us-gaap_EarningsPerShareTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration